Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yawei Ding
Observed name:
Ya-Wei Ding
Institutions:
Shanghai Medical College of Fudan University,
Fudan University
Observed institutions:
Shanghai Medical College of Fudan University,
Shanghai Jiao Tong University,
Fudan University,
Shanghai University of Medicine and Health Sciences,
Shanghai Sixth People's Hospital,
Shanghai Ocean University
show all 6
ORCID:
0000-0002-2879-3642
Observed ORCID:
0000-0002-2879-3642
OpenAlex ID:
A5033135361
Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules
2020
·
Xiang-Qi Zhang
, Ya-Wei Ding
, et al.
·
Journal of Ethnopharmacology
·
31
Tongguanteng Injection Reverses Paclitaxel Resistance Via Upregulation of TAB1 Expression in Ovarian Cancer in Vitro and in Vivo
2022
·
Qian-Wen Kong
, Jiao Yang
, et al.
·
Journal of Ethnopharmacology
·
15
Xiao-Ai-Ping Injection Enhances Effect of Paclitaxel to Suppress Breast Cancer Proliferation and Metastasis via Activating Transcription Factor 3
2020
·
Junjun Chen
, Xiangqi Zhang
, et al.
·
Integrative Cancer Therapies
·
11
PDF
Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression
2025
·
Kaifeng Jin
, Yawei Ding
, et al.
·
Journal for ImmunoTherapy of Cancer
·
7
PDF
Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study
2025
·
Zhaopei Liu
, Kaifeng Jin
, et al.
·
BMC Cancer
·
4
PDF
TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma
2025
·
Kaifeng Jin
, Jingtong Xu
, et al.
·
BMJ Oncology
·
4
PDF
Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma
2026
·
Yawei Ding
, Kaifeng Jin
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
Natural killer cell infiltration elicits gender‐dependent dichotomous clinical outcomes in urothelial carcinoma
2025
·
Lingkai Zhang
, Zhaopei Liu
, et al.
·
Cancer
·
2
ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
·
Clinical Cancer Research
·
2
PDF
Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma
2026
·
Jiaxing Sun
, Kaifeng Jin
, et al.
·
Cancer
·
1
TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma
2026
·
Xiaohe Su
, Kaifeng Jin
, et al.
·
British Journal of Cancer
Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression
2026
·
Lingkai Zhang
, Zhaopei Liu
, et al.
·
British Journal of Cancer
Data from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
Supplementary Figure S3 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Supplementary Figure S4 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Supplementary Figure S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Supplementary Table S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
Supplementary Figure S2 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Supplementary Table S2 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
Show more works
View as search
Works count:
19
Citation count:
79
H-index:
4
I10-index:
3
Year
Topic
Type